ABOSAcumen Pharmaceuticals, Inc.
The schedule
- Thu15Oct
An anticipated equity raise or ATM utilization to fund ongoing ACU193 clinical trials before current cash reserves are exhausted.
- Sun15Nov
A critical operational update regarding the enrollment progress and timeline for the Phase 2/2b study of ACU193, Acumen's lead Alzheimer's candidate.
- Tue9Feb
- Wed31Mar
Acumen Pharmaceuticals reported a Q4 net loss and highlighted a $305.5 million cash balance, which management noted would provide an operational runway into the first half of 2027. Despite this solid funding to support the ongoing Phase 2 ALTITUDE-AD trial for sabirnetug (ACU193), the stock declined significantly as rising R&D expenses and a lack of near-term clinical catalysts weighed on investor sentiment.
- Tue10Aug
Past
- Tue11Aug
Actual outcome: Bull · $2.74 at outcome
Acumen Pharmaceuticals reported Q2 earnings in line with expectations, with an EPS of -0.33 versus the estimate of -0.33. The company highlighted progress in its Phase II ALTITUDE-AD study for sabirnetug, an investigational Alzheimer's treatment, which signaled potential top-line results in late 2026. This positive development, combined with guidance on liquidity and cash runway, drove the stock higher despite the earnings miss.
Acumen will report Q2 earnings with a primary focus on liquidity, as its $51.8M cash reserve rapidly depletes against a ~$20.7M quarterly net loss.